Insmed (INSM) Other Non-Current Liabilities (2011 - 2026)
Insmed (INSM) posted Other Non-Current Liabilities of $170.5 million for Q2 2026, down 36.91% on a QoQ basis from $270.3 million in Q1 2026, and down 5.51% year-over-year from $180.5 million in Q2 2025.
Analysis
Insmed (INSM) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Insmed has reported Other Non-Current Liabilities for 16 years, with the latest figure at $170.5 million in Q2 2026.
- On a quarterly basis, Other Non-Current Liabilities fell 5.51% year-over-year to $170.5 million in Q2 2026; TTM through Jun 2026 was $170.5 million, a 5.51% decrease from a year earlier, with the FY2025 full-year figure at $314.3 million, up 117.99% from the prior year.
- Other Non-Current Liabilities was $170.5 million for Q2 2026 at Insmed, down from $270.3 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $314.3 million in Q4 2025, with the low at $38.6 million in Q1 2023.
- Average Other Non-Current Liabilities over 5 years is $127.0 million, with a median of $93.0 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities surged 611.12% in 2022, then plunged 41.62% in 2023.
- Over 5 years, Other Non-Current Liabilities stood at $51.1 million in 2022, then surged by 65.56% to $84.6 million in 2023, then surged by 70.45% to $144.2 million in 2024, then soared by 117.99% to $314.3 million in 2025, then slumped by 45.74% to $170.5 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $170.5 million (Q2 2026), $270.3 million (Q1 2026), and $314.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 170.55 Mn |
| Mar 31, 2026 | 270.31 Mn |
| Dec 31, 2025 | 314.34 Mn |
| Sep 30, 2025 | 259.60 Mn |
| Jun 30, 2025 | 180.50 Mn |
| Mar 31, 2025 | 159.90 Mn |
| Dec 31, 2024 | 144.20 Mn |
| Sep 30, 2024 | 157.60 Mn |
| Jun 30, 2024 | 101.50 Mn |
| Mar 31, 2024 | 63.70 Mn |
| Dec 31, 2023 | 84.60 Mn |
| Sep 30, 2023 | 69.90 Mn |
| Jun 30, 2023 | 46.40 Mn |
| Mar 31, 2023 | 38.60 Mn |
| Dec 31, 2022 | 51.10 Mn |
| Sep 30, 2022 | 51.80 Mn |
| Jun 30, 2022 | 55.60 Mn |
| Mar 31, 2022 | 66.12 Mn |
| Dec 31, 2021 | 75.67 Mn |
| Sep 30, 2021 | 76.49 Mn |